Kura Oncology, Inc. (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Several other brokerages have also commented on KURA. ValuEngine upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Citigroup Inc. set a $13.00 target price on Kura Oncology and gave the company a “buy” rating in a research report on Tuesday, August 8th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $16.00 target price on shares of Kura Oncology in a research report on Tuesday, July 4th. Leerink Swann restated an “outperform” rating and set a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a research report on Thursday, August 10th. Finally, Cowen and Company began coverage on Kura Oncology in a research report on Thursday, September 7th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $15.60.

Kura Oncology (NASDAQ KURA) traded down 2.26% during trading on Thursday, hitting $12.95. The stock had a trading volume of 1,610,746 shares. The stock has a 50 day moving average of $8.37 and a 200 day moving average of $8.90. The firm’s market capitalization is $258.84 million. Kura Oncology has a one year low of $4.00 and a one year high of $13.80.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. Equities research analysts expect that Kura Oncology will post ($1.53) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Kura Oncology, Inc. (KURA) Downgraded to “Hold” at Zacks Investment Research” was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/16/kura-oncology-inc-kura-downgraded-to-hold-at-zacks-investment-research.html.

Large investors have recently made changes to their positions in the business. State of Wisconsin Investment Board bought a new position in Kura Oncology in the second quarter worth approximately $102,000. Oppenheimer & Co. Inc. boosted its holdings in Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after acquiring an additional 1,600 shares in the last quarter. Segantii Capital Management Ltd bought a new position in Kura Oncology in the first quarter worth approximately $120,000. Rhumbline Advisers bought a new position in Kura Oncology in the second quarter worth approximately $131,000. Finally, Nationwide Fund Advisors bought a new position in Kura Oncology in the first quarter worth approximately $136,000. Institutional investors and hedge funds own 39.07% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.